New mRNA flu shot enters human testing
NCT ID NCT05945485
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 35 times
Summary
This early-stage study tests a new mRNA-based flu vaccine in 50 healthy adults aged 18 to 49. Participants receive two shots, 28 days apart, at different dose levels. The main goal is to check safety and how well the vaccine triggers an immune response, compared to a standard flu shot.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Iowa - Infectious Disease Clinic
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.